The cancer therapeutic efficacy of anthracyclines involves the induction of M1 and the downregulation of M2 macrophages [51] and the accumulation of immature macrophages (CD11b + F4/80 + Gr-1 (Ly6C/Ly6G+) [52]) and antigen-presenting cells (APC) exhibiting a dendritic cell-like (i.e., CD11b + .CD11c. This evidence concerns the gene ITGAM and cancer.